Integer (NYSE:ITGR) Stock Rating Reaffirmed by Benchmark

Integer (NYSE:ITGR)‘s stock had its “buy” rating restated by equities researchers at Benchmark in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $130.00 price objective on the medical equipment provider’s stock. Benchmark’s price objective would suggest a potential upside of 3.33% from the company’s current price.

A number of other research firms also recently issued reports on ITGR. Citigroup boosted their target price on shares of Integer from $124.00 to $130.00 and gave the company a “neutral” rating in a research report on Tuesday. Bank of America upped their price objective on shares of Integer from $135.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday. Oppenheimer assumed coverage on Integer in a research note on Tuesday, July 16th. They issued an “outperform” rating and a $135.00 target price for the company. Finally, Truist Financial increased their price target on Integer from $137.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $137.29.

Integer Price Performance

ITGR stock opened at $125.81 on Wednesday. The company has a quick ratio of 1.96, a current ratio of 3.29 and a debt-to-equity ratio of 0.73. The company’s fifty day simple moving average is $123.63 and its 200 day simple moving average is $119.41. Integer has a 12-month low of $69.40 and a 12-month high of $131.87. The firm has a market cap of $4.22 billion, a price-to-earnings ratio of 43.53, a PEG ratio of 1.87 and a beta of 1.09.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 EPS for the quarter, beating the consensus estimate of $1.24 by $0.06. The company had revenue of $436.20 million for the quarter, compared to analyst estimates of $437.00 million. Integer had a return on equity of 11.48% and a net margin of 6.31%. The firm’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.14 EPS. On average, analysts expect that Integer will post 5.31 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Jean M. Hobby sold 11,960 shares of Integer stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the transaction, the director now owns 2,280 shares of the company’s stock, valued at $272,824.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 2.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ITGR. Quest Partners LLC increased its stake in Integer by 3,688.9% in the 2nd quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 332 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Integer by 60.9% in the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 142 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Integer during the first quarter valued at approximately $106,000. Innealta Capital LLC bought a new stake in Integer during the second quarter worth $110,000. Finally, Hancock Whitney Corp purchased a new position in Integer in the first quarter worth $203,000. 99.29% of the stock is owned by institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.